Caricamento...

Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with doses escalating from 50 to 150 mg daily for 12 weeks. Response kinetics suggested that more prolonged administration of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood
Autori principali: Winkler, Thomas, Fan, Xing, Cooper, James, Desmond, Ronan, Young, David J., Townsley, Danielle M., Scheinberg, Phillip, Grasmeder, Sophia, Larochelle, Andre, Desierto, Marie, Valdez, Janet, Lotter, Jennifer, Wu, Colin, Shalhoub, Ruba N., Calvo, Katherine R., Young, Neal S., Dunbar, Cynthia E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2019
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6566590/
https://ncbi.nlm.nih.gov/pubmed/30992268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000478
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !